Sandoz Group AG (OTCMKTS:SDZNY) Sees Significant Decline in Short Interest

Sandoz Group AG (OTCMKTS:SDZNY) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 54,700 shares, a decrease of 85.1% from the February 13th total of 366,500 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 53,600 shares, the short-interest ratio is presently 1.0 days.

Sandoz Group Price Performance

OTCMKTS:SDZNY traded up $1.36 on Thursday, hitting $42.18. The company’s stock had a trading volume of 32,202 shares, compared to its average volume of 41,940. The stock has a fifty day moving average of $45.39 and a two-hundred day moving average of $43.93. Sandoz Group has a one year low of $27.79 and a one year high of $49.81.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. UBS Group lowered Sandoz Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 3rd. BNP Paribas lowered Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 2nd.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.